Source: Brazilian Journal of Medical and Biological Research. Unidade: FMRP
Subjects: NEOPLASIAS MAMÁRIAS, QUIMIOTERAPIA ADJUVANTE, PROGNÓSTICO
ABNT
BUZATTO, I. P. C. et al. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors. Brazilian Journal of Medical and Biological Research, v. 50, n. 2, 2017Tradução . . Disponível em: https://doi.org/10.1590/1414-431x20165674. Acesso em: 22 ago. 2024.APA
Buzatto, I. P. C., Ribeiro-Silva, A., Andrade, J. M. de, Carrara, H. H. A., & Tiezzi, D. G. (2017). Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors. Brazilian Journal of Medical and Biological Research, 50( 2). doi:10.1590/1414-431x20165674NLM
Buzatto IPC, Ribeiro-Silva A, Andrade JM de, Carrara HHA, Tiezzi DG. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors [Internet]. Brazilian Journal of Medical and Biological Research. 2017 ; 50( 2):[citado 2024 ago. 22 ] Available from: https://doi.org/10.1590/1414-431x20165674Vancouver
Buzatto IPC, Ribeiro-Silva A, Andrade JM de, Carrara HHA, Tiezzi DG. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors [Internet]. Brazilian Journal of Medical and Biological Research. 2017 ; 50( 2):[citado 2024 ago. 22 ] Available from: https://doi.org/10.1590/1414-431x20165674